Technical Data
I8432-11A
Interleukin 10, Recombinant, Human (IL-10, Cytokine Synthesis Inhibitory Factor, CSIF)
2ug
10ug
10ug
|
Technical Data |
|
I8432-11A |
Interleukin 10, Recombinant, Human (IL-10, Cytokine Synthesis Inhibitory Factor, CSIF) |
2ug 10ug |
| Growth Factors, Cytokines | Storage: -20°CShipping: RT |
|
Interleukin-10 is produced by murine T-cells following their stimulation by lectins. The main source for B-cell-derived Interleukin-10 in mice are Ly-1 B-cells that express CD5 and CD11. Murine keratinocytes also produce IL10. In humans IL-10 is produced by activated CD8(+) peripheral blood T-cells, by T-helper CD4 (+) T-cell clones (resembling Th0, Th1, and Th2) after both antigen-specific and polyclonal activation, by B-cell lymphomas, and by monocytes following cell activation by bacterial lipopolysaccharides and mast cells. B-cell lines derived from patients with acquired immunodeficiency syndrome and Burkitt's lymphoma constitutively secrete large quantities of IL-10 into the conditioned medium. The synthesis of IL-10 by monocytes is inhibited by IL-4 and IL-10. Recombinant Human IL-10 is a single, glycosylated polypeptide chain containing 161 amino acids and having a molecular mass of 18.6kD. Sequence: The sequence of the first five N-terminal amino acids was determined and was found to be Ser-Pro-Gly-Gln-Thr. Biological Activity: Interleukin-10 is fully biologically active when compared to standard. The ED50 as determined by the dose-dependent co-stimulation with murine IL-4 of MC-9 cells was found to be < 2ng/ml, corresponding to a Specific Activity of 1.5 x 10e7 IU/mg. Recommended Dilution: Optimal dilutions to be determined by the researcher. Storage and Stability: Lyophilized powder may be stored at -20°C. Stable for 12 months at -20°C. Reconstitute with sterile buffer or ddH2O. Aliquot to avoid repeated freezing and thawing. Store at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer. Molecular Weight: 18.6kD |
Source: Recombinant, Human (CHO cells) Purity: 98% by RP-HPLC, FPLC, or reducing/non-reducing SDS-PAGE Silver Stain. Chromatographically purified. Endotoxin: Less than 0.1ng/ug (IEU/ug) . Concentration: ~0.1mg/ml Form: Supplied as a lyophilized powder in 60mM PBS, pH 6.5, 100mM sodium chloride. Reconstitute with sterile ddH2O, 0.1% HSA or BSA to a concentration of 0.1mg/ml, which can then be further diluted to other aqueous solutions. Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological. |
|
1. Prognostic role of Ebstein-Barr virus latent membrane protein-1 and interleukin-10 expression in patients with nasopharyngeal carcinoma. Ozyar E, Ayhan A, Atahan IL, Cancer Invest 2004;22(4):483-91 2. Accelerated prion disease in the absence of interleukin-10. Thackray AM, McKenzie AN, Lauder A, J Virol 2004 Dec;78(24):13697-707 3. Dehydroepiandrosterone suppresses interleukin 10 synthesis in women with systemic lupus erythematosus. Chang DM, Chu SJ, Kuo SY, Ann Rheum Dis 2004 Dec;63(12):1623-6 4. Increased ratio of tumor necrosis factor-alpha to interleukin-10 production is associated with Schistosoma haematobium-induced urinary-tract morbidity. Wamachi AN, Mayadev JS, Magak PL, Koech DK, J Infect Dis 2004 Dec 1;190(11):2020-30 5. Maternal infection-induced white matter injury is reduced by treatment with interleukin-10. Rodts-Palenik S, Wyatt-Ashmead J, Thigpen B, Granger J, Am J Obstet Gynecol 2004 Oct;191(4):1387-92 6. Interleukin-10 (IL-10) counterregulates IL-4-dependent effector mechanisms in Murine Filariasis. Specht S, Volkmann L, Hoerauf A, Infect Immun 2004 Nov;72(11):6287-93.
|
||